Acurx Pharmaceuticals (ACXP) Shares Outstanding (2020 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Shares Outstanding (Entity) came in at $2.7 million in Q1 2026, up 142.74% YoY from $1.1 million in Q1 2025, and up 81.37% on a QoQ basis from $1.5 million in Q4 2025.
Acurx Pharmaceuticals (ACXP) Shares Outstanding (2020 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 7 years of Shares Outstanding (Entity) data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 142.74% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 142.74% YoY) and the FY2025 annual result came in at $1.5 million, up 76.01% from the prior year.
- Shares Outstanding (Entity) advanced to $2.7 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.7 million in Q1 2026 to a low of $513160.0 in Q1 2022.
- A 5-year average of $964719.2 and a median of $787855.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 12.18% — and 2026, when it soared 142.74%.
- Tracing ACXP's Shares Outstanding (Entity) over 5 years: stood at $581380.0 in 2022, then grew by 24.43% to $723411.0 in 2023, then grew by 17.71% to $851534.0 in 2024, then surged by 76.01% to $1.5 million in 2025, then soared by 81.37% to $2.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $2.7 million (Q1 2026), $1.5 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Mar 31, 2026 | 2.72 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 808,168.00 |
| Sep 30, 2024 | 818,174.00 |
| Jun 30, 2024 | 791,233.00 |
| Mar 31, 2024 | 773,625.00 |
| Dec 31, 2023 | 633,579.00 |
| Sep 30, 2023 | 650,256.00 |
| Jun 30, 2023 | 609,324.00 |
| Mar 31, 2023 | 581,970.00 |
| Dec 31, 2022 | 540,821.00 |
| Sep 30, 2022 | 557,420.00 |
| Jun 30, 2022 | 513,160.00 |
| Mar 31, 2022 | 511,642.00 |
| Dec 31, 2021 | 426,794.00 |
| Sep 30, 2021 | 505,820.00 |